GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Pre-Tax Income

Halberd (Halberd) Pre-Tax Income : $ Mil (TTM As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Halberd's pretax income for the six months ended in Jul. 2023 was $-0.45 Mil. Halberd does not have enough years/quarters to calculate the pretax income for the trailing twelve months (TTM) ended in Jul. 2023. Halberd's pretax margin was -15,133.33%.

During the past 3 years, Halberd's highest Pretax Margin was -757.14%. The lowest was -20312.50%. And the median was -15133.33%.


Halberd Pre-Tax Income Historical Data

The historical data trend for Halberd's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Pre-Tax Income Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Pre-Tax Income
-0.05 -1.63 -0.45

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Pre-Tax Income -0.05 -1.63 -0.45

Competitive Comparison of Halberd's Pre-Tax Income

For the Biotechnology subindustry, Halberd's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halberd's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Halberd's Pre-Tax Income falls into.



Halberd Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Halberd's Pretax Income for the fiscal year that ended in Jul. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.447+0+-0.007+0+0
=-0.45

Halberd's Pretax Income for the quarter that ended in Jul. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.447+0+-0.007+0+0
=-0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Halberd  (OTCPK:HALB) Pre-Tax Income Explanation

Halberd's Pretax Margin for the quarter that ended in Jul. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-0.454/0.003
=-15,133.33%

During the past 3 years, Halberd's highest Pretax Margin was -757.14%. The lowest was -20312.50%. And the median was -15133.33%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Halberd Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Halberd's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236